CN118477076A - 用于治疗pik3ca相关过度生长综合征群的方法 - Google Patents

用于治疗pik3ca相关过度生长综合征群的方法 Download PDF

Info

Publication number
CN118477076A
CN118477076A CN202410563611.0A CN202410563611A CN118477076A CN 118477076 A CN118477076 A CN 118477076A CN 202410563611 A CN202410563611 A CN 202410563611A CN 118477076 A CN118477076 A CN 118477076A
Authority
CN
China
Prior art keywords
byl719
pros
pik3ca
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410563611.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡诺德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Dais Paris, University of
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Western Dais Paris, University of
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Dais Paris, University of, Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Western Dais Paris, University of
Publication of CN118477076A publication Critical patent/CN118477076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
CN202410563611.0A 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法 Pending CN118477076A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)
CN201780011659.9A CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780011659.9A Division CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Publications (1)

Publication Number Publication Date
CN118477076A true CN118477076A (zh) 2024-08-13

Family

ID=55409795

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410563611.0A Pending CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN201780011659.9A Pending CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780011659.9A Pending CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Country Status (8)

Country Link
US (4) US11433059B2 (https=)
EP (1) EP3416642A1 (https=)
JP (3) JP7051693B2 (https=)
KR (1) KR20180115297A (https=)
CN (3) CN118477076A (https=)
AU (3) AU2017219834B2 (https=)
CA (1) CA3013845C (https=)
WO (1) WO2017140828A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016265844B2 (en) 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)
KR20210124310A (ko) 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
JP2024516006A (ja) * 2021-05-03 2024-04-11 ノバルティス アーゲー アルペリシブ製剤
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357B (zh) * 2006-08-29 2013-03-20 新加坡国立癌症中心 Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
AU2016265844B2 (en) * 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
EP3416642A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)

Also Published As

Publication number Publication date
AU2017219834B2 (en) 2022-06-30
US11433059B2 (en) 2022-09-06
JP2022058800A (ja) 2022-04-12
JP7847994B2 (ja) 2026-04-20
EP3416642A1 (en) 2018-12-26
KR20180115297A (ko) 2018-10-22
JP2019505549A (ja) 2019-02-28
US20250339417A1 (en) 2025-11-06
CA3013845C (en) 2024-09-17
AU2022235569A1 (en) 2022-10-13
CN109562103A (zh) 2019-04-02
US12427141B2 (en) 2025-09-30
US20250295645A1 (en) 2025-09-25
AU2022235569B2 (en) 2024-10-10
JP2024125429A (ja) 2024-09-18
JP7051693B2 (ja) 2022-04-11
AU2017219834A1 (en) 2018-08-23
CN118477075A (zh) 2024-08-13
WO2017140828A1 (en) 2017-08-24
US20200215044A1 (en) 2020-07-09
CA3013845A1 (en) 2017-08-24
AU2024278598A1 (en) 2025-01-16
US20220323428A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US12427141B2 (en) BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome)
EP2959894B1 (en) S1p receptor modulators for treating multiple sclerosis
US11723911B2 (en) Treatment of demyelinating diseases
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
CN110511266B (zh) 一种小分子多肽及其用途
US11318186B2 (en) Use of FGF21 in methods of increasing exocrine pancreatic secretion
JP2007511522A (ja) 血管新生およびがん細胞増殖の調節方法
JP7168228B2 (ja) 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
Górska Diffuse alveolar hemorrhage in a chronically hemodialyzed patient with progressive necrotic skin lesions as a manifestation of calciphylaxis
Feng et al. The role of CC motif chemokine ligand 2 in the preservation of myogenic tone in the kidney microvasculature of Dahl Salt-Sensitive rats
WO2018027149A1 (en) Methods of treating alport syndrome
WO2014065370A1 (ja) 肺高血圧症治療剤
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
JP2024020797A (ja) 筋萎縮の治療剤
WO2026021460A1 (zh) 治疗前列腺癌的方法
Chen et al. 1Department of Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, No. 136, Jingzhou Street, Xiangcheng District, Xiangyang 441021, Hubei, China. 2Department of Emergency Medicine, Xiangyang Central Hospital
HK1214758B (en) S1p receptor modulators for treating multiple sclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination